List of Excipients in Branded Drug CLONIDINE HCI

« Back to Dashboard

Generic Drugs Containing CLONIDINE HCI

Company	Ingredient	NDC	Excipient
HF Acquisition Co LLC DBA HealthFirst	clonidine hci	51662-1346	HYDROCHLORIC ACID
HF Acquisition Co LLC DBA HealthFirst	clonidine hci	51662-1346	SODIUM CHLORIDE
HF Acquisition Co LLC DBA HealthFirst	clonidine hci	51662-1346	SODIUM HYDROXIDE
HF Acquisition Co LLC DBA HealthFirst	clonidine hci	51662-1346	WATER

What are the Most Frequently-Used Excipients in CLONIDINE HCI?

# Of NDCs	Excipient
1	HYDROCHLORIC ACID
1	SODIUM CHLORIDE
1	SODIUM HYDROXIDE
1	WATER

Clonidine HCl Excipient Strategy and Commercial Opportunities

Last updated: October 8, 2026

Clonidine hydrochloride is a mature, low-cost active pharmaceutical ingredient with commercial opportunities concentrated in differentiated delivery systems, pediatric formulations, adherence products, and manufacturing efficiency. The strongest formulation positions are extended-release oral products, palatable liquid dosage forms, orally disintegrating tablets, and transdermal or depot technologies that manage clonidine’s short half-life and dose-related hypotension.

What dosage forms use clonidine hydrochloride?

Clonidine hydrochloride is used primarily in immediate-release tablets, extended-release tablets, oral solutions or suspensions, and extemporaneously compounded pediatric liquids. Transdermal clonidine products generally use clonidine rather than clonidine hydrochloride in the drug reservoir or matrix.

Dosage form	Primary use	Excipient priority	Commercial position
Immediate-release tablet	Hypertension, off-label withdrawal and pain-related uses	Low-cost compression, stability, dose uniformity	Highly commoditized
Extended-release tablet	ADHD and related symptom management	Controlled release, dose dumping prevention, mechanical strength	Higher differentiation
Oral solution or suspension	Pediatric and dysphagia populations	Taste masking, suspension stability, preservative control	Attractive niche
Orally disintegrating tablet	Patients with swallowing difficulty and adherence needs	Fast disintegration, low friability, taste masking	Potential line extension
Transdermal system	Hypertension and adherence-sensitive treatment	Adhesion, permeation control, reservoir stability	Device-led opportunity
Multiparticulate or sprinkle product	Pediatric and flexible dosing	Coating, dose uniformity, food compatibility	Development opportunity

The FDA-approved extended-release product Kapvay established clonidine hydrochloride as an ADHD formulation platform, while immediate-release clonidine products remain widely available as low-cost generics. FDA labeling distinguishes immediate-release and extended-release pharmacokinetics, making release control a central CMC and regulatory issue (U.S. Food and Drug Administration [FDA], 2010a; FDA, 2010b).

What excipients are used in clonidine hydrochloride tablets?

Approved clonidine hydrochloride tablets typically use conventional solid-dose excipients, including microcrystalline cellulose, lactose, starch or pregelatinized starch, colloidal silicon dioxide, stearic acid, and other tablet lubricants or disintegrants. The exact composition varies by manufacturer and strength.

Immediate-release tablet excipient strategy

The immediate-release product is sensitive to cost because clonidine hydrochloride is a generic, high-volume, low-price molecule. A competitive formulation should prioritize:

• Direct compression or low-step wet granulation.
• Robust content uniformity at low drug loading.
• Low friability at small tablet sizes.
• Simple excipient sourcing from multiple qualified suppliers.
• Stable performance across 0.1 mg and 0.2 mg strengths.
• Minimal color and coating complexity.

Clonidine hydrochloride is potent relative to tablet mass. Low-dose uniformity is therefore more important than bulk flow alone. Microcrystalline cellulose, anhydrous lactose, mannitol, or dibasic calcium phosphate can provide tablet mass, but the selected diluent must support blend uniformity and avoid segregation.

Crospovidone, croscarmellose sodium, and sodium starch glycolate can support rapid disintegration. Excessive lubricant concentration or over-lubrication can slow dissolution and create scale-up variability. Magnesium stearate level, blending time, and compression force should be treated as critical process variables.

Extended-release tablet excipient strategy

Extended-release clonidine hydrochloride requires a release-control system that maintains exposure over the intended dosing interval without producing rapid systemic absorption. Hydrophilic matrix systems are commercially practical because they can use established excipients such as hypromellose, polyethylene oxide, or selected grades of cellulose polymers.

Key formulation controls include:

1. Polymer viscosity and substitution grade.
2. Tablet hardness and porosity.
3. Drug-to-polymer ratio.
4. Manufacturing scale and mixing energy.
5. Release behavior in physiologically relevant media.
6. Resistance to alcohol-induced dose dumping.
7. Food-effect performance.

The release profile must be clinically meaningful. A formulation that produces a slower in vitro release rate may still fail if it changes peak concentration, trough concentration, or sedation and hypotension risk. FDA labeling for extended-release clonidine instructs that the product should not be substituted with immediate-release clonidine on a milligram-for-milligram basis because the pharmacokinetic profiles differ (FDA, 2010a).

Pediatric excipient strategy

Pediatric products create the clearest excipient opportunity. The active ingredient has a bitter or otherwise difficult taste profile, and pediatric dosing often requires flexible volumes. A commercial formulation should address:

• Taste masking without delaying absorption excessively.
• Low viscosity for accurate administration.
• Dose uniformity after shaking.
• Sedimentation and redispersibility.
• Compatibility with oral syringes.
• Limited preservative burden.
• Low sugar content where chronic use is expected.
• Stability after opening.
• Flexible dose measurement for titration.

Potential taste-masking approaches include ion-exchange resins, polymeric coating, cyclodextrin complexes, lipid-based barriers, and sweetener-flavor systems. Ion-exchange resins can create a differentiated product if the complex remains stable in the mouth but releases clonidine in the gastrointestinal tract.

Suspensions offer formulation flexibility but introduce settling, caking, and dosing variability. Solutions provide better dose uniformity but may require pH adjustment, cosolvents, solubilizers, and stronger taste-masking systems. A low-volume, concentrated suspension can reduce administration burden but increases the importance of syringe accuracy and labeling.

What formulations are protected by clonidine hydrochloride patents?

The original composition-of-matter protection for clonidine hydrochloride is long expired. Commercial protection now depends on formulation architecture, delivery technology, method of use, manufacturing process, and regulatory exclusivity rather than the active molecule itself.

Potentially protectable features include:

• Extended-release matrix composition.
• Multilayer tablet structure.
• Coated multiparticulates.
• Taste-masked clonidine particles.
• Stable oral liquid with defined pH and preservative system.
• Transdermal permeation-control matrix.
• Specific dosing regimens for ADHD or withdrawal-related conditions.
• Combination products with stimulant or nonstimulant therapies.
• Manufacturing processes that improve content uniformity at low dose.

A formulation patent must provide a meaningful technical distinction from earlier clonidine products. Broad claims directed only to clonidine hydrochloride in a tablet are vulnerable to invalidity and obviousness challenges. Stronger claims typically define release profiles, excipient ranges, particle coatings, dissolution limits, stability parameters, or clinically relevant pharmacokinetic characteristics.

When does clonidine hydrochloride lose exclusivity?

Immediate-release clonidine hydrochloride has already lost basic market exclusivity. Generic competition is established, and the commercial barrier is primarily manufacturing scale, regulatory compliance, pharmacy distribution, and contracting.

Extended-release clonidine products also face generic competition once applicable patents and regulatory exclusivities expire. The practical launch date depends on:

• Approved ANDA status.
• Paragraph IV certification and litigation.
• 30-month stay, if triggered.
• Any pediatric exclusivity.
• Product-specific patents listed in the Orange Book.
• FDA approval timing.
• State substitution and payer formulary policy.

Protection category	Clonidine HCl position
Active ingredient patent	Expired
Immediate-release tablet exclusivity	Expired
Extended-release formulation protection	Product- and patent-specific
Pediatric exclusivity	Historical or product-specific
Orphan exclusivity	Generally not central to the commercial market
Biosimilar protection	Not applicable because clonidine hydrochloride is a small molecule
Orange Book relevance	Applies to listed drug products and listed patents, not to the molecule generally

What is the Orange Book status of clonidine hydrochloride?

The Orange Book is relevant to approved branded and generic drug products, including listed patents and therapeutic-equivalence information. Immediate-release clonidine hydrochloride tablets are generally evaluated through standard ANDA pathways. Extended-release products may have more complex product-specific patent and equivalence issues.

For a generic applicant, the key Orange Book questions are:

1. Which reference listed drug is designated for the intended dosage form?
2. Are formulation or method-of-use patents listed?
3. Is a Paragraph IV certification required?
4. Does the product require comparative pharmacokinetic studies, pharmacodynamic studies, or in vitro release comparisons?
5. Does the applicant need a suitability petition or a different reference product?
6. Are the proposed strengths and release characteristics therapeutically equivalent?

A clonidine hydrochloride applicant should not assume that an immediate-release generic pathway applies to an extended-release product. Modified-release dosage forms may require additional comparative testing, dissolution modeling, food-effect studies, and dose-dumping evaluation.

Which companies are challenging clonidine hydrochloride patents?

The immediate-release market is already populated by generic manufacturers, including large U.S. generic companies and contract manufacturers. Publicly visible patent challenges are more likely to arise around extended-release products, novel delivery systems, or line extensions than around conventional immediate-release tablets.

Paragraph IV risk is highest when a generic applicant targets:

• A branded extended-release tablet.
• A patented liquid formulation.
• A transdermal system with listed device or formulation claims.
• A product with a narrow formulation patent estate.
• A product with limited alternative reference products.

A conventional immediate-release tablet generally has low patent risk but high price pressure. An extended-release or taste-masked product may have higher patent exposure but also provides more pricing and market-segmentation potential.

What patent litigation affects clonidine hydrochloride products?

Patent litigation risk depends on the specific reference product and the current Orange Book listing. The highest-value disputes would concern extended-release clonidine products used in ADHD, because a successful generic could affect a differentiated prescription market rather than only a low-price hypertension market.

Typical litigation issues include:

• Claim construction for release-control polymers.
• Obviousness of hydrophilic matrix systems.
• Anticipation by older clonidine formulations.
• Written-description support for excipient ranges.
• Enablement of broad release-profile claims.
• Infringement based on dissolution testing.
• Validity of method-of-use claims.
• Regulatory carve-outs for non-patented indications.

Settlement agreements may include delayed generic entry, licensing rights, authorized-generic arrangements, or restrictions tied to particular indications. Commercial diligence should distinguish patent settlement terms from FDA approval status because an approved ANDA does not necessarily mean immediate market entry.

How strong is the clonidine hydrochloride patent estate?

The patent estate is weak for conventional immediate-release tablets and potentially moderate for technically differentiated products. Strength depends on claim scope, prior-art density, enforceability, and the ease with which a generic can design around the formulation.

Product concept	Patent strength	Generic substitution risk	Commercial potential
Standard immediate-release tablet	Low	High	Low margin, high volume
Conventional oral solution	Low to moderate	Moderate to high	Moderate niche
Taste-masked pediatric suspension	Moderate	Moderate	Attractive if clinically preferred
Extended-release matrix tablet	Moderate	Moderate	Stronger margin potential
Multiparticulate sprinkle product	Moderate to high	Moderate	Pediatric and adherence opportunity
Transdermal delivery system	Moderate to high	Lower initially	Device and formulation driven
Novel combination product	Product-specific	Product-specific	Potentially high, but regulatory risk rises

Patent strength improves when the formulation solves a measurable problem, such as reduced peak-related adverse effects, improved pediatric acceptability, lower dosing frequency, or reduced variability after food intake.

What FDA regulatory pathway applies to new clonidine formulations?

A conventional generic tablet typically follows the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. A materially different dosage form, new route of administration, new indication, or clinically differentiated formulation may require a 505(b)(2) application.

Development objective	Likely pathway
Same immediate-release tablet	ANDA
Same extended-release tablet	ANDA with product-specific equivalence requirements
New oral suspension	ANDA or 505(b)(2), depending on reference and formulation differences
New transdermal system	Often 505(b)(2) or a device-drug pathway
New indication or dosing regimen	505(b)(2) or supplemental NDA
Novel combination product	505(b)(2), NDA, or combination-product review

A 505(b)(2) strategy can support differentiated excipient systems, liquid formulations, or delivery platforms when the sponsor relies partly on FDA findings for an approved clonidine product. The tradeoff is greater clinical, CMC, and regulatory investment than a standard ANDA.

What commercial opportunities exist for clonidine hydrochloride excipients?

Preservative-controlled pediatric liquids

A stable, palatable liquid with a low preservative burden could compete in pediatric ADHD and specialty-care settings. Unit-dose packaging, ready-to-use bottles, and oral-syringe compatibility can support institutional and caregiver use.

Taste-masked ADHD products

Extended-release clonidine is used in pediatric populations where swallowing and adherence can limit treatment. A sprinkle capsule, mini-tablet, or taste-masked suspension could expand use among children unable to swallow tablets.

Low-volume concentrated formulations

A concentrated product can reduce dosing volume, shipping weight, and administration burden. The risk is medication error from concentration confusion, requiring clear labeling and calibrated dosing devices.

Orally disintegrating tablets

An orally disintegrating clonidine product could target patients with dysphagia, psychiatric comorbidities, or adherence barriers. The key technical risks are taste, friability, rapid absorption, and accidental administration errors.

Transdermal and depot systems

Clonidine’s pharmacology supports delivery systems that reduce peak-trough fluctuation and dosing frequency. Adhesive failure, skin irritation, dose delivery consistency, and heat-related exposure are the main product-development risks.

Excipient supplier opportunities

Suppliers can create value through:

• Low-moisture direct-compression grades.
• Functional coating polymers.
• Ion-exchange resins for taste masking.
• Controlled-release hypromellose grades.
• Ready-to-use suspending vehicles.
• Preservative-free multidose systems.
• Co-processed excipients for low-dose uniformity.
• Packaging systems that protect liquid stability.

The commercial opportunity is strongest where an excipient produces a measurable product advantage and can support formulation patent claims or regulatory differentiation.

How does clonidine hydrochloride compare with competing ADHD drugs?

Clonidine extended release competes with guanfacine extended release, stimulant products, atomoxetine, and newer nonstimulants. Its commercial advantages include established pharmacology, low active-ingredient cost, and utility in patients who cannot tolerate stimulants. Its disadvantages include sedation, hypotension, bradycardia, and the need for careful discontinuation to reduce rebound hypertension risk.

Attribute	Clonidine HCl ER	Guanfacine ER	Stimulant products
Core formulation opportunity	Release control and pediatric acceptability	Release control and pediatric acceptability	Abuse deterrence, duration, and delivery
Sedation risk	Material	Material, often differentiated clinically	Generally lower but varies
Generic pressure	High	High to moderate, product-specific	Varies by product
Excipient value	Taste masking and controlled release	Similar	Delivery and abuse-deterrence systems
Patent value	Formulation-dependent	Formulation- and method-dependent	Often higher for novel delivery systems

Key Takeaways

• Clonidine hydrochloride is a mature small molecule with limited value in conventional immediate-release tablets.
• The strongest commercial opportunities are pediatric liquids, taste-masked products, extended-release systems, orally disintegrating tablets, and transdermal platforms.
• Excipients should be selected around low-dose uniformity, release control, taste, suspension stability, and dose-dumping resistance.
• Immediate-release clonidine has high generic substitution risk and low pricing power.
• Extended-release and pediatric formulations can support greater differentiation and stronger patent positions.
• Biosimilar risk does not apply because clonidine hydrochloride is a small-molecule drug.
• FDA pathway selection depends on whether the product is therapeutically equivalent to an approved reference or introduces a new dosage form, route, indication, or delivery technology.
• Patent value is strongest when the excipient system produces a clinically relevant and difficult-to-design-around performance advantage.

FAQs

Can clonidine hydrochloride be formulated without preservatives?

Yes. A preservative-free product can use unit-dose packaging, sterile or controlled manufacturing where appropriate, or a validated multidose container system. The commercial choice depends on microbiological risk, package design, in-use stability, and cost.

Is clonidine hydrochloride suitable for an extended-release suspension?

It can be technically suitable, but the formulation must control sedimentation, redispersibility, dose uniformity, and release after administration. A suspension may require a 505(b)(2) strategy if it differs materially from approved reference products.

Which excipient is best for clonidine hydrochloride taste masking?

No single excipient is universally preferred. Ion-exchange resins, polymer coatings, lipid barriers, cyclodextrins, and sweetener-flavor systems each offer different release and stability profiles. The best choice depends on dosage form, target population, and required release rate.

Does clonidine hydrochloride have biosimilar competition?

No. Biosimilar regulation applies to biological products. Clonidine hydrochloride is a chemically synthesized small molecule and competes through generic drug pathways.

Can a new clonidine formulation receive market exclusivity?

Potentially. A new formulation may obtain patent protection and, depending on the regulatory pathway and clinical development, product-specific exclusivity. Exclusivity is not automatic and depends on the approval basis, indication, and statutory requirements.

References

1. U.S. Food and Drug Administration. (2010a). Kapvay (clonidine hydrochloride) extended-release tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2010b). Catapres (clonidine hydrochloride) tablets: Prescribing information.
3. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. DailyMed. (2024). Clonidine hydrochloride tablet and extended-release tablet labeling. National Library of Medicine.